WT1 Gene Overexpression in Oncohematological Disorders: Theoretical and Clinical Aspects (Literature Review)

Nikolai Nikolaevich Mamaev, Ya.V. Gudozhnikova, A.V. Gorbunova,

DOI:

https://doi.org/10.21320/2500-2139-2016-9-3-257-264

The article discusses recent data on the WT1 gene overexpression phenomenon in patients with acute leukemias, myelodysplastic syndromes, chronic myeloid leukemia, non-Hodgkin’s lymphomas, and multiple myeloma. It demonstrates that monitoring of the WT1 gene overexpression proves to be effective during the posttransplantation period, as well as after the induction chemotherapy. This approach may be applied in diagnosing the minimal residual disease and early detection of leukemia relapses, as well as their timely and controlled treatment. There are other promising fields of research, such as testing autografts for the presence or absence of tumor elements, as well as evaluation of the efficacy of induction chemotherapy in high risk patients.

  • Nikolai Nikolaevich Mamaev R.M. Gorbacheva Scientific Research Institute of Pediatric Hematology and Transplantation; Academician I.P. Pavlov First St. Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
  • Ya.V. Gudozhnikova R.M. Gorbacheva Scientific Research Institute of Pediatric Hematology and Transplantation; Academician I.P. Pavlov First St. Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
  • A.V. Gorbunova R.M. Gorbacheva Scientific Research Institute of Pediatric Hematology and Transplantation; Academician I.P. Pavlov First St. Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
  1. Call KM, Glaser T, Ito CI, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor gene locus. Cell. 1990;60(3):509–20. doi: 10.1016/0092-8674(90)90601-a. DOI: https://doi.org/10.1016/0092-8674(90)90601-A
  2. Rose EA, Glaser T, Jones C, et al. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms’ tumor gene. Cell. 1990;60(3):495–508. doi: 10.1016/0092-8674(90)90600-j. DOI: https://doi.org/10.1016/0092-8674(90)90600-J
  3. Miwa H, Beran M, Saunders GF. Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia. 1992;6(5):405–9.
  4. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms’ tumour gene (WT1) in human leukemia. Blood. 1997;88(4):1405–12. DOI: https://doi.org/10.1182/blood.V89.4.1405
  5. Абдулкадыров К.М., Грицаев С.В., Капустин С.И. и др. Экспрессия гена опухоли Вилмса (WT1) в клетках крови больных миелодиспластическим синдромом. Вопросы онкологии. 2004;50(6):668–71.
  6. [Abdulkadyrov KM, Gritsaev SV, Kapustin SI, et al. Wilms’ tumor gene (WT1) expression in blood cells of patients with myelodysplastic syndrome. Voprosy oncologii. 2004;50(6):668–71. (In Russ)]
  7. Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: The WT1 story. Leukemia. 2007;21(5):868–76. doi: 1038/sj.leu.2404624. DOI: https://doi.org/10.1038/sj.leu.2404624
  8. Мамаев Н.Н., Горбунова А.В., Гиндина Т.Л. и др. Аллогенная трансплантация гемопоэтических стволовых клеток при миелодиспластических синдромах и клиническое значение гиперэкспрессии гена WT1. Клиническая онкогематология. 2014;7(4):551–63. DOI: https://doi.org/10.21320/2500-2139-2014-7-4-551-563
  9. [Mamayev NN, Gorbunova AV, Gindina TL, et al. Allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and clinical significance of WT1 gene overexpression. Klinicheskaya onkogematologiya. 2014;7(4):551–63. (In Russ)]
  10. Мамаев Н.Н., Горбунова А.В., Бархатов И.М. и др. Молекулярный мониторинг течения острых миелоидных лейкозов по уровню экспрессии гена WT1 после аллогенной трансплантации гемопоэтических столовых клеток. Клиническая онкогематология. 2015;8(3):309–20. doi: 10.21320/2500-2139-2015-8-3-309-320.
  11. [Mamaev NN, Gorbunova AV, Barkhatov IM, et al. Molecular monitoring of WT1 gene expression level in acute myeloid leukemias after allogeneic hematopoietic stem cell transplantation. Clinical oncohematology. 2015;8(3):309–20. doi: 10.21320/2500-2139-2015-8-3-309-320. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2015-8-3-309-320
  12. Israyelyan A, Goldstein L, Tsai W, et al. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(1):26–33. doi: 10.1038/bmt.2014.209. DOI: https://doi.org/10.1038/bmt.2014.209
  13. Iwasaki T, Sugisaki Ch, Nagata K, et al. Wilms’ tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia. Pathol Int. 2007;57(10):645–51. doi: 10.1111/j.1440-2007.02153.x. DOI: https://doi.org/10.1111/j.1440-1827.2007.02153.x
  14. Tatsumi N, Hojo N, Yamada O, et al. Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. Oncogene. 2015;35(8):1003–14. doi: 10.1038/onc.2015.154. DOI: https://doi.org/10.1038/onc.2015.154
  15. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84(9):3071–9. DOI: https://doi.org/10.1182/blood.V84.9.3071.3071
  16. Drakos E, Rassidakis GZ, Tsioli F, et al. Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem. Mol Morphol. 2005;13(2):132–7. doi: 10.1097/01.pai.0000143786.62974.66. DOI: https://doi.org/10.1097/01.pai.0000143786.62974.66
  17. Hatta Y, Takeuchi J, Saitoh T, et al. WT1 expression level and clinical factors in multiple myeloma. J Exp Clin Cancer Res. 2005;24(4):595–9.
  18. Na I-K, Kreuzer K-A, Lupberger J, et al. Quantitative RT-PCR of Wilms tumor gene transcripts(WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. Leuk Res. 2005;29(3):343–5. doi: 10.1016/j.leukres.2004.08.003. DOI: https://doi.org/10.1016/j.leukres.2004.08.003
  19. Chiusa L, Francia di Celle P, Campisi P, et al. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica. 2006;91(2):270–1. doi: 10.0000/www.haematologica.org/content/91/2/270.short.
  20. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103(8):2794–7. doi: 10.1073/pnas.0510423103. DOI: https://doi.org/10.1073/pnas.0510423103
  21. Cao X, Gu WY, Chen ZX, et al. Bone marrow WT1 gene expression and clinical significance in chronic myelogenous leukemia. Zhonghua Nei Ke Za Zhi. 2007;46(4):277–9.
  22. Otahalova E, Ullmannova-Benson V, Klamova FI, et al. WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of imatinib resistance. Neoplasma. 2009;56(5):393–7. doi: 10.4149/neo_2009_05_393. DOI: https://doi.org/10.4149/neo_2009_05_393
  23. Heesch S, Goekbuget N, Stroux A, et al. Prognostic implications and expression of the Wilms tumor 1 (WT1) gene in adult T-lymphoblastic leukemia. 2010;95(6):942–9. doi: 10.3324/haematol.2009.016386. DOI: https://doi.org/10.3324/haematol.2009.016386
  24. Аксенова Е.В. Стандартизированное исследование экспрессии генов BCR-ABL, PRAME и WT1 у больных хроническим миелолейкозом: Диc. ¼ канд. мед. наук. М., 2011. 138 с.
  25. [Aksyenova EV. Standartizirovannoe issledovanie expressii genov BCR-ABL, PRAME I WT1 u bolnykh chronicheskim myeloleukosom. (Standardized evaluation of the BCR-ABL, PRAME and WT1 gene expression in patients with chronic myeloid leukemia.) [dissertation] Moscow; 2011. 138 p. (In Russ)]
  26. Гапонова Т.В. Экспрессия опухолеассоциированных генов PRAME, WT1 и XIAP у больных множественной миеломой в процессе интенсивной терапии и аутотрансплантации: Диc. ¼ канд. мед. наук. М., 2011. 141 с.
  27. [Gaponova TV. Expressia opucholeassocirovannykh genov PRAME, WT1 i XIAP u bolnykh mnozhestvennoi myelomoi v processe intensivnoi therapii I autotransplantacii. (Tumor-associated PRAME, WT1 and XIAP gene expression in patients with multiple myeloma during intensive therapy and autografting.) [dissertation] Moscow; 2011. 141 p. (In Russ)]
  28. Tyler EM, Jungbluth AA, O’Reilly RJ, Koehne G. WT1-specific responses in high-risk multiple myeloma patients undergoing allogeneic T-cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. 2012;121(2):308–17. doi: 10.1182/blood-2012-06-435040. DOI: https://doi.org/10.1182/blood-2012-06-435040
  29. Ujj Z, Buglyo G, Udvardy M, et al. WT1 overexpression affecting clinical outcome in non-Hodgkin lymphomas and adult acute lymphoblastic leukemia. Pathol Oncol Res. 2013;20(3):565–70. doi: 10.1007/s12253-013-9729- DOI: https://doi.org/10.1007/s12253-013-9729-7
  30. Inoue K, Ogawa H, Yamagami T, et al. Long–term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood. 1996;88(6):2267–78. DOI: https://doi.org/10.1182/blood.V88.6.2267.bloodjournal8862267
  31. Kletzel N, Olzewski M, Huang W, et al. Utility of WT1 as a reliable tool for the detection of minimal disease in children with leukemia. Pediatr Dev Pathol. 2002;5(3):269–75. doi: 10.1007/s10024-001-0208-x. DOI: https://doi.org/10.1007/s10024-001-0208-x
  32. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring residual disease in acute leukemia patients. 2002;16(10):2115–21. doi: 10.1038/sj.leu.2402675. DOI: https://doi.org/10.1038/sj.leu.2402675
  33. Cilloni D, Giuseppe S, Gottardi E, et al. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Hematol. 2004;112(1–2):79–84. doi: 10.1159/000077562. DOI: https://doi.org/10.1159/000077562
  34. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–201. doi: 10.1200/jco.2009.22.4865. DOI: https://doi.org/10.1200/JCO.2009.22.4865
  35. Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RTPCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. 2005;19(8):1416–23. doi: 10.1038/sj.leu.2403809. DOI: https://doi.org/10.1038/sj.leu.2403809
  36. Candoni A, Toffoletti E, Gallina R, et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant. 2011;25(2):308–16. doi: 10.1111/j.1399-0012.2010.01251.x. DOI: https://doi.org/10.1111/j.1399-0012.2010.01251.x
  37. Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-transplantation. Leuk Res. 2012;36(4):453–8. doi: 10.1016/j.leukres.2011.09.005. DOI: https://doi.org/10.1016/j.leukres.2011.09.005
  38. Kwon M, Martinez-Laperche C, Infante M, et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms’ Tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell trans-plantation: Correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant. 2012;18(8):1235–42. doi: 10.1016/j.bbmt.2012.01.012. DOI: https://doi.org/10.1016/j.bbmt.2012.01.012
  39. Polak J, Hajkova H, Haskovec C, et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia – a useful tool for early detection of minimal residual disease. 2013;60(1):74–82. doi: 10.4149/neo_2013_011. DOI: https://doi.org/10.4149/neo_2013_011
  40. Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93(6):921–4. doi: 10.3324/haematol.12165. DOI: https://doi.org/10.3324/haematol.12165
  41. Andersson C, Li X, Lorenz F, et al. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol. 2012;21(4):225–33. doi: 10.1097/pdm.0b013e318257ddb9. DOI: https://doi.org/10.1097/PDM.0b013e318257ddb9
  42. Mossallam GI, Hamid TM, Mahmoud HK, et al. Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients. Hematology. 2013;18(2):69–73. doi: 10.1179/1607845412Y.0000000048. DOI: https://doi.org/10.1179/1607845412Y.0000000048
  43. Ujj Z, Buglyo G, Udvardy M, et al. WT1 expression in adult acute myeloid leukemia: Assessing its presence, magnitude and temporal changes as prognostic factors. Pathol Oncol Res. 2015;22(1):217–21. doi: 10.1007/s12253-015-0002- DOI: https://doi.org/10.1007/s12253-015-0002-0
  44. Rein LAM, Chao NJ. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. Expert Opin Invest Drugs. 2014;23(3):417–26. doi: 10.1517/13543784.2014.889114. DOI: https://doi.org/10.1517/13543784.2014.889114
  45. Paschka P, Marcucci G, Ruppert A.S, et al. Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2008;26(28):4595–602. doi: 10.1200/jco.2007.15.2058. DOI: https://doi.org/10.1200/JCO.2007.15.2058
  46. Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40(5):377–87. doi: 10.1093/jjco/hyp194. DOI: https://doi.org/10.1093/jjco/hyp194
  47. Vidovic K, Svensson T, Nilsson B, et al. Wilms’ tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. Leukemia. 2010;24(5):9982–1000. doi: 10.1038/leu.2010.33. DOI: https://doi.org/10.1038/leu.2010.33
  48. Essafi A, Webb A, Berry RL, et al. A WT1-controlled chromatin switching mechanism underpins tissue-specific wnt4 activation and repression. Dev Cell. 2011;21(3):559–74. doi: 10.1016/j.devcel.2011.07.014. DOI: https://doi.org/10.1016/j.devcel.2011.07.014
  49. Huff V. Wilms’ tumours: about tumour suppressor genes, an oncogene and chameleon gene. Nat Rev Cancer. 2001;11(2):111–21. doi: 10.1038/nrc3002. DOI: https://doi.org/10.1038/nrc3002
  50. Morrison AA, Viney RL, Landomery MR. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta. 2008;1785(1):55–62. doi: 10.1016/j.bbcan.2007.10.002. DOI: https://doi.org/10.1016/j.bbcan.2007.10.002
  51. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukemias. Hematol Onc 2010;28(1):13–9. doi: 10.1002/hon.931. DOI: https://doi.org/10.1002/hon.931
  52. Haber DA, Sohn RL, Buckler AJ, et al. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA. 1991;88(21):9618–22. doi: 10.1073/pnas.88.21.9618. DOI: https://doi.org/10.1073/pnas.88.21.9618
  53. Keilholz U, Menssen HD, Gaiger A, et al. Wilms’ tumor gene 1(WT1) in human neoplasia. 2005;19(8):1318–23. doi: 10.1038/sj.leu.2403817. DOI: https://doi.org/10.1038/sj.leu.2403817
  54. Hosen N, Shirakata T, Nishida S, et al. The Wilms’ tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia. 2007;21(8):1783–91. doi: 10.1038/sj.leu.2404752. DOI: https://doi.org/10.1038/sj.leu.2404752
  55. Miller-Hodges E, Hohenstein P. WT1 in disease: shifting the epithelial-mesenchymal balance. J Pathol. 2012;226(2):229–40. doi: 10.1002/path.2977. DOI: https://doi.org/10.1002/path.2977
  56. Cunningham TJ, Palumbo I, Grosso M, et al. WT1 regulates murine hematopoiesis via maintenance of VEGF isoform ratio. Blood. 2013;122(2):188–92. doi: 10.1182/blood-2012-11-466086. DOI: https://doi.org/10.1182/blood-2012-11-466086
  57. Patmasirivat P, Fraizer G, Kantarjian H, Saunders GF. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia. 1999;13(6):891–900. doi: 10.1038/sj.leu.2401414. DOI: https://doi.org/10.1038/sj.leu.2401414
  58. Gaiger A, Linnerth B, Mann G, et al. Wilms’ tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukemia treated by an intensive chemotherapy protocol. Eur J Haematol. 2009;63(2):86–93. doi: 10.1111/j.1600-0609.1999.tb01121.x. DOI: https://doi.org/10.1111/j.1600-0609.1999.tb01121.x
  59. Arlyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant hematopoiesis. Expert Rev Mol Med. 2007;9(14):1–17. doi: 10.1017/s1462399407000336. DOI: https://doi.org/10.1017/S1462399407000336
  60. Ellisen LW, Carlesso N, Cheng T, et al. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20(8):1897–909. doi: 10.1093/emboj/20.8.1897. DOI: https://doi.org/10.1093/emboj/20.8.1897
  61. Scharnhorst V, van den Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273(2):141–61. doi: 10.1016/s0378-1119(01)00593-5. DOI: https://doi.org/10.1016/S0378-1119(01)00593-5
  62. Baird PN, Simmons PJ. Expression of the Wllms’ tumor gene (WT1) in normal hematopoiesis. Eur Haematol. 1997;25(4):312–20.
  63. Lange T, Hubmann M, Burkhard R, et al. Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. 2011;25(3):498–505. doi: 10.1038/leu.2010.283. DOI: https://doi.org/10.1038/leu.2010.283
  64. Schmid D, Heinze G, Linnert B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia. 1997;11(5):639–43. doi: 10.1038/sj.leu.2400620. DOI: https://doi.org/10.1038/sj.leu.2400620
  65. Lyu X, Xin Y, Mi R, et al. Overexpression of Wilms’ Tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. PLoS One. 2014;9(3):e92470. doi: 10.1371/journal.pone.0092470. DOI: https://doi.org/10.1371/journal.pone.0092470
  66. Wochlecke C, Wittig S, Arndt C, Gruhn B. Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases. J Cancer Res Clin. Oncol. 2014;141(3):523–9. doi: 10.1007/s00432-014-1832-y. DOI: https://doi.org/10.1007/s00432-014-1832-y
  67. Zhao X-S, Jin S, Zhu H-H, et al. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;47(4):499–507. doi: 10.1038/bmt.2011.121. DOI: https://doi.org/10.1038/bmt.2011.121
  68. Nomdedeu JF, Hoyos M, Carricondo M, et al. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia. 2013;27(11):2157–64. doi: 10.1038/leu.2013.111. DOI: https://doi.org/10.1038/leu.2013.111
  69. Alonso-Domingues JM, Tenorio M, Velasco D, et al. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genet. 2012;205(4):190–1. doi: 10.1016/j.cancergen.2012.02.008. DOI: https://doi.org/10.1016/j.cancergen.2012.02.008
  70. Tamaki H, Ogawa H, Inoue K, et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood. 1996;88(11):4396–8. DOI: https://doi.org/10.1182/blood.V88.11.4396b.bloodjournal88114396b
  71. Frairia C, Aydin S, Riera L, et al. WT1 expression in аcute myeloid leukaemia: a useful marker for improving therapy response evaluation. 2013;122(21):2588 (abstract). DOI: https://doi.org/10.1182/blood.V122.21.2588.2588
  72. Willasch AM, Gruhn B, Coliva T, et al. Standartization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. 2009;23(8):1472–9. doi: 10.1038/leu.2009.51. DOI: https://doi.org/10.1038/leu.2009.51
  73. Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24(10):1507–15. doi: 10.1200/jco.2005.03.5303. DOI: https://doi.org/10.1200/JCO.2005.03.5303
  74. Liu J, Wang Yu, Xu L-P, et al. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia-rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(7):929–36. doi: 10.1016/j.bbmt.2014.03.008. DOI: https://doi.org/10.1016/j.bbmt.2014.03.008
  75. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101(5):1698–704. doi: 10.1182/blood-2002-06- DOI: https://doi.org/10.1182/blood-2002-06-1831
  76. Yoon JH, Kim HJ, Shin SH, et al. BAALC and WT1 expression from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. Eur J Haematol. 2013;91(2):112–21. doi: 10.1111/ejh.12142. DOI: https://doi.org/10.1111/ejh.12142
  77. Yoon JH, Kim H-J, Kim J-W, et al. Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation. Bone Marrow Transplant. 2014;49(12):1466–74. doi: 10.1038/bmt.2014.180. DOI: https://doi.org/10.1038/bmt.2014.180
  78. Miyagi T, Ahuja H, Kudota T, et al. Expression of the candidate Wilms’ tumor gene, WT1, in human leukemia cells. Leukemia. 1993;7(7):970–7.
  79. Miyawaki S, Hatsumi N, Tamaki T, et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma. 2010;51(10):1855–61. doi: 10.3109/10428194.2010.507829. DOI: https://doi.org/10.3109/10428194.2010.507829
  80. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat. 1997;9(3):209–25. doi: 10.1002/(sici)1098-1004(1997)9:3<209::aid-humu2>3.0.co;2-2. DOI: https://doi.org/10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2
  81. Mori N, Okada M, Motoji T, et al. Mutation of the WT1 gene in myelodysplastic syndrome and acute myeloid leukemia post myelodysplastic syndrome. Br J Haematol. 1999;105(3):844–5. doi: 10.1046/j.1365-1999.01497.x. DOI: https://doi.org/10.1046/j.1365-2141.1999.01497.x
  82. Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010;28(4):578–85. doi: 10.1200/jco.2009.23.0342. DOI: https://doi.org/10.1200/JCO.2009.23.0342
  83. Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115(25):5222–31. doi: 10.1016/s1040-1741(10)79528- DOI: https://doi.org/10.1016/S1040-1741(10)79528-2
  84. Shen Y, Zhu Y-M, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593–603. doi: 10.1182/blood-2011-03- DOI: https://doi.org/10.1182/blood-2011-03-343988
  85. Luo S, Yu K, Yan QX, et al. Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2014;56(2):349–57. doi: 10.3109/10428194.2013.791985. DOI: https://doi.org/10.3109/10428194.2013.791985
  86. Park SH, Lee HJ, Kim I-S, et al. Incidences and prognostic impact of c-KIT, WT1, CEBPA, and CBL mutations, and mutations associated with epigenetic modification in core binding factor acute myeloid leukemia: a multicenter study in Korean population. Ann Lab Med. 2015;35(3):288–97. doi: 10.3343/alm.2015.35.3.288. DOI: https://doi.org/10.3343/alm.2015.35.3.288
  87. Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9(5):1841–55. doi: 10.1016/j.celrep.2014.11.004. DOI: https://doi.org/10.1016/j.celrep.2014.11.004
  88. Zhang Q, Zhang Q, Li Q. Monitoring of WT1 and its target gene IRF8 expression in acute myeloid leukemia and their significance. Int J Lab Hematol. 2015;37(4):e67–71. doi: 10.1111/ijlh.12309. DOI: https://doi.org/10.1111/ijlh.12309
  89. Brieger J, Weidmann E, Fenchel K, et al. The expression of the Wilms’ tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia. 1994;8(12):2138.
  90. Brieger J, Weidmann E, Maurer U, et al. The Wilms’ tumor gene is frequently expressed in acute myeloblastic leukemia and may provide a marker for residual blast cells detectable by PCR. Ann Oncol. 1995;6(8):811–66. DOI: https://doi.org/10.1093/oxfordjournals.annonc.a059321
  91. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997;90(3):1217–25. DOI: https://doi.org/10.1182/blood.V90.3.1217
  92. Ogawa H, Ikegame K, Kawakami M, Tamaki H. WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk Lymphoma. 2004;45(9):1747–53. doi: 10.1080/10428190410001687503. DOI: https://doi.org/10.1080/10428190410001687503
  93. Rodrigues PC, Oliveira SN, Vaina MB, et al. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2007;49(2):133–8. doi: 10.1002/pbc.20953. DOI: https://doi.org/10.1002/pbc.20953
  94. Miglino M, Colombo N, Pica C, et al. Wt1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2011;52(10):1961–9. doi: 10.3109/10428194.2011.585673. DOI: https://doi.org/10.3109/10428194.2011.585673
  95. Zhao BR, Tang XW, Cen JN, et al. Correlation between clinical outcome and WT1 detection after hematopoietic stem cell transplantation in acute leukemia. Zhonghua Yi Xue Za Zhi. 2011;91(20):1375–8.
  96. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia. 1998;12(12):1886–94. doi: 10.1038/sj.leu.2401213. DOI: https://doi.org/10.1038/sj.leu.2401213
  97. Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica. 2004;89(8):926–33.
  98. Yi-ning Y, Xiao-rui W, Chu-xian Z, et al. Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analyse. Ann Hematol. 2015;94(6):929–38. doi: 10.1007/s00277-014-2295- DOI: https://doi.org/10.1007/s00277-014-2295-6
  99. Nowakowska-Kopera A, Sacha T, Florek I, et al. Wilms’ tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk Lymphoma. 2009;50(8):1326–32. doi: 10.1080/10428190903050021. DOI: https://doi.org/10.1080/10428190903050021
  100. Guillaumet-Adkins A, Richter J, Odera MD, et al. Hypermethylation of the alternative AWT1 promotor in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. J Hematol Oncol. 2014;7(1):4. doi: 10.1186/1756-8722-7-4. DOI: https://doi.org/10.1186/1756-8722-7-4
  101. Capelli D, Attolico I, Saraceli F, et al Early cumulative incidence of relapse in 80 acute myeloid leukemia patients after chemotherapy and transplant post-consolidation treatment: prognostic role of post-induction WT1. 40th EBMT Meeting; 2014 30 March – 2 April; Milan, Italy; 2014: Abstract P287.
  102. Messina C, Candoni A, Carraba MG, et al. Wilms’ tumor gene 1 transcript levels in leukopheresis on peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. Biol Blood Marrow Transpl. 2014;20(10):1586–91. doi: 10.1016/j.bbmt.2014.06.017. DOI: https://doi.org/10.1016/j.bbmt.2014.06.017
  103. Messina C, Sala E, Carrabba M, et al. Early post-allogeneic transplantation WT1 transcript positivity predicts AML relapse. 40th EBMT Meeting; 2014 30 March – 2 April; Milan, Italy; 2014: Abstract P239. DOI: https://doi.org/10.1155/2014/123079
  104. Gianfaldoni G, Mannelli F, Ponziani V, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica. 2010;95(5):833–6. doi: 10.3324/haematol.2009.011908. DOI: https://doi.org/10.3324/haematol.2009.011908
  105. Мамаев Н.Н., Горбунова А.В., Гиндина Т.Л. и др. Трансплантация гемопоэтических стволовых клеток при остром миелоидном лейкозе с транслокацией t(8;21)(q22;q22). Клиническая онкогематология. 2013;6(4):439–44. DOI: https://doi.org/10.21320/2500-2139-2013-6-4-439-444
  106. [Mamayev NN, Gorbunova AV, Gindina TL, et al. Hemopoietic stem cell transplantation in AML patients with t(8;21)(q22;q22) translocation. Klinicheskaya onkogematologiya. 2013;6(4):439–44. (In Russ)]
  107. Мамаев Н.Н., Горбунова А.В., Гиндина Т.Л. и др. Стойкое восстановление донорского гемопоэза у больной с посттрансплантационным рецидивом острого миеломонобластного лейкоза с inv(3)(q21q26), моносомией 7 и экспрессией онкогена EVI1 после трансфузий донорских лимфоцитов и использования гипометилирующих агентов. Клиническая онкогематология. 2014;7(1):71–5. DOI: https://doi.org/10.21320/2500-2139-2014-7-1-71-75
  108. [Mamayev NN, Gorbunova AV, Gindina TL, et al. Stable donor hematopoiesis reconstitution after post-transplantation relapse of acute myeloid leukemia in patient with inv(3)(q21q26), –7 and EVI1 oncogene overexpression treated by donor lymphocyte infusions and hypomethylating agents. Klinicheskaya onkogematologiya. 2014;7(1):71–5. (In Russ)]
  109. Barragan E, Pajuelo JC, Ballester S, et al. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta. 2008;395(1–2):120–3. doi: 10.1016/j.cca.2008.05.021. DOI: https://doi.org/10.1016/j.cca.2008.05.021
  110. Ostergaard M, Olesen LH, Hasle H, et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukemia patients – results from a single-centre study. Br J Haematol. 2004;125(5):590–600. doi: 10.1111/j.1365-2004.04952.x. DOI: https://doi.org/10.1111/j.1365-2141.2004.04952.x
  111. Zhao XS, Yan CH, Liu DH, et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol. 2013;92(8):1111–9. doi: 10.1007/s00277-013-1733- DOI: https://doi.org/10.1007/s00277-013-1733-1
  112. Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol. 2009;82(1):61–8. doi: 10.1111/j.1600-2008.01158.x. DOI: https://doi.org/10.1111/j.1600-0609.2008.01158.x
  113. Ommen HB, Nyvold CG, Braendstrup K, et al. Relapse prediction in acute myeloid leukemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol. 2008;141(6):782–991. doi: 10.1111/j.1365-2008.07132.x. DOI: https://doi.org/10.1111/j.1365-2141.2008.07132.x
  114. Yamauchi T, Negoro E, Lee S, et al. Detectable Wilms’ tumor-1 transcription at treatment completion is associated with poor prognosis of acute myeloid leukemia: a single institution’s experience. Anticancer Res. 2013;33(8):3335–40.
  115. Woehlecke C, Wittig S, Sanft J, et al. Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism. J Cancer Res Clin Oncol. 2015;141(7):1283–90. doi: 10.1007/s00432-015-1919- DOI: https://doi.org/10.1007/s00432-015-1919-0
  116. Jin S, Liu DH, Xu LP, et al. The significance of dynamic detection of WT1 expression on patients of hematologic malignancy following allogeneic hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi. 2008;47(7):578–81.
  117. Rossi G, Minervini MM, Carella AM, et al. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res. 2012;36(4):401–6. doi: 10.1016/j.leukres.2011.11.020. DOI: https://doi.org/10.1016/j.leukres.2011.11.020
  118. Zhao Q, Zhao Q, Li Q, et al. Monitoring of WT1 and its target gene IRF8 expression in acute myeloid leukemia and their significance. Int J Lab Hematol. 2014;37(4):e67–71. doi: 10.1111/ijlh.12309. DOI: https://doi.org/10.1111/ijlh.12309
  119. Mear J-B, Salaun V, Dina N, et al. WT1 and flow cytometry minimal residual disease follow-up after allogeneic transplantation in practice. 40th EBMT Meeting; 2014 30 March – 2 April; Milan, Italy; 2014: Abstract P655.
  120. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. 1999;13(3):393–9. doi: 10.1038/sj.leu.2401341. DOI: https://doi.org/10.1038/sj.leu.2401341
  121. Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Scoring System score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21(10):1988–95. doi: 10.1200/jco.2003.10.503. DOI: https://doi.org/10.1200/JCO.2003.10.503
  122. Bader P, Niemeyer C, Weber G, et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. Eur J Haematol. 2004;73(1):25–8. doi: 10.1111/j.1600-2004.00260.x. DOI: https://doi.org/10.1111/j.1600-0609.2004.00260.x
  123. Tamura H, Dan K, Yokose N, et al. Prognostic significance of WT1 mRNA and antiWT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res. 2010;34(8):986–90. doi: 10.1016/j.leukres.2009.11.029. DOI: https://doi.org/10.1016/j.leukres.2009.11.029
  124. Yamauchi T, Matsuda Y, Takai M, et al. Wilms’ tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia. Anticancer Res. 2012;32(10):4479–83.
  125. Qin Y-Z, Zhu H-H, Liu Y-R, et al. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. Leuk Lymphoma. 2013;54(7):1442–9. doi: 10.3109/10428194.2012.743656. DOI: https://doi.org/10.3109/10428194.2012.743656
  126. Ueda Y, Mizutani C, Nannya Y, et al. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma. 2013;54(7):1450–18. doi: 10.3109/10428194.2012.745074. DOI: https://doi.org/10.3109/10428194.2012.745074
  127. Minetto P, Guolo F, Clavio M, et al. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndrome. Leuk Res. 2015;39(8):866–73. doi: 10.1016/j.leukres.2015.04.011. DOI: https://doi.org/10.1016/j.leukres.2015.04.011
  128. Santamaria C, Ramos F, Puig N, et al. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. Ann Hematol. 2012;91(12):1887–95. doi: 10.1007/s00277-012-1538- DOI: https://doi.org/10.1007/s00277-012-1538-7
  129. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms’ tumor gene wt1 transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995;9(6):1060–7.
  130. He YZ, Liang Z, Wu MR, et al. Overexpression of EPS8 is associated with poor prognosis in patients with acute lymphoblastic leukemia. Leuk Res. 2015;39(6):575–81. doi: 10.1016/j.leukres.2015.03.007. DOI: https://doi.org/10.1016/j.leukres.2015.03.007
  131. Xu B, Song S, Yip NC, et al. Simultaneous detection of MDR and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology. 2010;15(2):74–80 doi: 10.1179/ 102453310X12583347009937. DOI: https://doi.org/10.1179/102453310X12583347009937
  132. Azuma T, Otsuki T, Kuzushima K, et al. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2004;10(21):7402–12. doi: 10.1158/1078-ccr-04-0825. DOI: https://doi.org/10.1158/1078-0432.CCR-04-0825
  133. Hamalainen MM, Kairisto V, Junonen V, et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukemia. Eur J Haematol. 2008;80(3):201–7. doi: 10.1111/j.1600-2007.01009.x. DOI: https://doi.org/10.1111/j.1600-0609.2007.01009.x
  134. Wartheim GB, Bagg A. Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. Expert Rev Mol Drug. 2011;11(4):361–6. doi: 10.1586/erm.11.19. DOI: https://doi.org/10.1586/erm.11.19
  135. Lambert J, Lambert J, Niboured O, et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 2014;5(15):6280–8. doi: 10.18632/oncotarget.2196. DOI: https://doi.org/10.18632/oncotarget.2196
  136. Steinbach D, Bader P, Willasch A, et al. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myeloid leukemia. Clin Cancer Res. 2014;21(6):1353–9. doi: 10.1158/1078-ccr-14-1999. DOI: https://doi.org/10.1158/1078-0432.CCR-14-1999
  137. Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leuk Res. 2012;36(4):453–8. doi: 10.1016/j.leukres.2011.09.005. DOI: https://doi.org/10.1016/j.leukres.2011.09.005
  138. Noronha SA, Farrar JE, Alonzo TA, et al. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the children’s oncology group. Pediatr Blood Cancer. 2009;53(6):1136–9. doi: 10.1002/pbc.22142. DOI: https://doi.org/10.1002/pbc.22142
  139. Kim HJ, Choi EJ, Sohn HJ, et al. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia. Eur J Haematol. 2013;91(5):411–22. doi: 10.1111/ejh.12167. DOI: https://doi.org/10.1111/ejh.12167
  140. Niavarani A, Currie E, Reyal Y, et al. APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts. PloS One. 2015;10(3):e0120089. doi: 10.1371/journal.pone.0120089. DOI: https://doi.org/10.1371/journal.pone.0120089
  141. Taira C, Matsuda K, Kamijyo Y, et al. Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course. Clin Chim Acta. 2011;412(1–2):53–8. doi: 10.1016/j.cca.2010.09.011. DOI: https://doi.org/10.1016/j.cca.2010.09.011
  142. Morita Y, Heike1 Y, Kawakami M, et al. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int J Cancer. 2006;119(6):1360–7. doi: 10.1002/ijc.21960. DOI: https://doi.org/10.1002/ijc.21960
  143. Tsuboi A, Oka Y, Nakajima H, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 2007;86(5):414–7. doi: 10.1007/bf02983998. DOI: https://doi.org/10.1007/BF02983998
  144. Narita M, Masuko M, Kurasaki T, et al. WT1 peptide vaccination in combination with imatinib for a patient with CML in the chronic phase. Int J Med Sci. 2010;7(2):72–81. doi: 10.7150/ijms.7.72. DOI: https://doi.org/10.7150/ijms.7.72

Keywords:

WT1 gene overexpression phenomenon, hematopoietic stem cell transplantation, chemotherapy, molecular treatment monitoring

License

Copyright (c) 2016 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Nikolai Nikolaevich Mamaev, DSci, Professor, R.M. Gorbacheva Scientific Research Institute of Pediatric Hematology and Transplantation; Academician I.P. Pavlov First St. Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022, НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022, e-mail: nikmamaev524@gmail.com
2016-3

Downloads

Published

01.07.2016

Issue

Vol. 9 No. 3 (2016)
REVIEWS

How to Cite

Mamaev N.N., Gudozhnikova Y.V., Gorbunova A.V. WT1 Gene Overexpression in Oncohematological Disorders: Theoretical and Clinical Aspects (Literature Review). Clinical Oncohematology. Basic Research and Clinical Practice. 2016;9(3):257–264. doi:10.21320/2500-2139-2016-9-3-257-264.

Most read articles by the same author(s)

1 2 > >>